PD-1 is a novel regulator of human B-cell activation

Thibult, Marie-Laure; Mamessier, Emilie; Gertner-Dardenne, Julie; Pastor, Sonia; Just-Landi, Sylvaine; Xerri, Luc; Chetaille, Bruno; Olive, Daniel

doi:10.1093/intimm/dxs098

Cited by 365T-cell and B-cell ImmunologyCancer Immunotherapy and BiomarkersImmune Response and Inflammation

PD-1 is a novel regulator of human B-cell activation

Thibult, Marie-Laure, Mamessier, Emilie, Gertner-Dardenne, Julie, Pastor, Sonia, Just-Landi, Sylvaine, Xerri, Luc, Chetaille, Bruno, Olive, Daniel·2013·International Immunology

DOI 10.1093/intimm/dxs098

Open this paper in CoChat — free account

Abstract

The outcome of the adaptive immune response is determined by the integration of both positive and negative signals, respectively, induced upon the triggering of co-signaling receptors. One of them, programmed cell death 1 (PDCD1/PD-1) has largely been shown to be involved in the negative regulation of T-cell activation. However, PD-1 is also expressed on human B cells, and its role(s) in the process of human B-cell activation remains uncertain thus far. In this study, we describe the expression of PD-1 on the major human B-cells subsets isolated from peripheral blood and lymph nodes. We showed that PD-1 was expressed on naive B cells, was differentially expressed on peripheral IgM memory as compared with memory B cells and was lost on germinal center B cells. Expression of PD-1 ligands (PD-Ls) was induced by TLR9 activation. Finally, we showed that PD-1 was recruited to the B-cell receptor upon triggering. We determined that during TLR9 activation, blockade of PD-1/PD-Ls pathways indeed increased B-cell activation, proliferation and the production of inflammatory cytokines. Altogether, our results show, that, as reported in T cells, PD-1/PD-Ls complexes acted as inhibitors of the B-cell activation cascade and highlight the importance of devising future therapies able to modulate lymphocyte activation through the targeting of the PD-1/PD-Ls pathways.

Integrity signals

Registry

Crossref · 10.1093/intimm/dxs098

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Inhibition of the PD-1/PD-L1 pathway may also have T cell-independent effects.
“Since other cell types (such as dendritic cells and B cells) can also be influenced by PD-1 signaling, inhibition of the PD-1/PD-L1 pathway may also have T cell-independent effects, whose impact on immune responses during checkpoint inhibitor therapy remain to be elucidated (36, 58).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [36]

Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · see citing works
Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,259 · see citing works
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955 · see citing works
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in <i>Ctla-4</i>
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766 · see citing works
Points of control in inflammation
Nathan, C. (2002) · Nature · doi:10.1038/nature01320 · Cited by 2,738 · see citing works
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496 · see citing works
The B7 family revisited
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318 · see citing works
Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses
Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.016 · Cited by 1,733 · see citing works
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubat, T., Yagita, H., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.765 · Cited by 1,589 · see citing works
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 <sup>+</sup> T lymphocytes are prognostic factors of human ovarian cancer
Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378 · see citing works
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314 · see citing works
Human Immunoglobulin (Ig)M+IgD+ Peripheral Blood B Cells Expressing the CD27 Cell Surface Antigen Carry Somatically Mutated Variable Region Genes: CD27 as a General Marker for Somatically Mutated (Memory) B Cells
Klein, U., Rajewsky, K., & Küppers, R. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.9.1679 · Cited by 1,161 · see citing works
Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma
Rosenwald, A., Wright, G. W., Leroy, K., Yu, X., Gaulard, P., Gascoyne, R. D., Chan, W. C., Zhao, T., Haïoun, C., Greiner, T. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20031074 · Cited by 1,095 · see citing works
Expression of Programmed Death 1 Ligands by Murine T Cells and APC
Yamazaki, T., Akiba, H., Iwai, H., Matsuda, H., Aoki, M., Tanno, Y., Shin, T., Tsuchiya, H., Pardoll, D. M., Okumura, K., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.10.5538 · Cited by 950 · see citing works
Cloning of B7-2: a CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation
Freeman, G. J., Gribben, J. G., Boussiotis, V. A., Ng, J. W., Restivo, V. A., Lombard, L. A., Gray, G. S., & Nadler, L. M. (1993) · Science · doi:10.1126/science.7694363 · Cited by 903 · see citing works
BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1
Watanabe, N., Gavrieli, M., Sedy, J. R., Yang, J., Fallarino, F., Loftin, S. K., Hurchla, M. A., Zimmerman, N., Sim, J., Zang, X., et al. (2003) · Nature Immunology · doi:10.1038/ni944 · Cited by 883 · see citing works
B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells
Tseng, S.-Y., Otsuji, M., Gorski, K. S., Huang, X., Slansky, J. E., Pai, S. I., Shalabi, A., Shin, T., Pardoll, D. M., & Tsuchiya, H. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.7.839 · Cited by 867 · see citing works
PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine
Okazaki, T., Maeda, A., Nishimura, H., Kurosaki, T., & Honjo, T. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231486598 · Cited by 849 · see citing works
Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire
Weller, S. (2004) · Blood · doi:10.1182/blood-2004-01-0346 · Cited by 816 · see citing works
The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice
Ansari, M. J., Salama, A. D., Chitnis, T., Smith, R. N., Yagita∥, H., Akiba, H., Yamazaki, T., Azuma, M., Iwai, H., Khoury, S. J., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022125 · Cited by 806 · see citing works
Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer
Ohigashi, Y., Sho, M., Yamada, Y., Tsurui, Y., Hamada, K., Ikeda, N., Mizuno, T., Yoriki, R., Kashizuka, H., Yane, K., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1469 · Cited by 796 · see citing works
PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells
Good‐Jacobson, K. L., Szumilas, C. G., Chen, L., Sharpe, A. H., Tomayko, M. M., & Shlomchik, M. J. (2010) · Nature Immunology · doi:10.1038/ni.1877 · Cited by 694 · see citing works
Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies
Berger, R., Rotem‐Yehudar, R., Slama, G., Landes, S., Kneller, A., Leiba, M., Koren‐Michowitz, M., Shimoni, A., & Nagler, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4079 · Cited by 680 · see citing works
Human Immunoglobulin M Memory B Cells Controlling Streptococcus pneumoniae Infections Are Generated in the Spleen
Krützmann, S. A.-C., Rosado, M. M., Weber, H., Germing, U., Tournilhac, O., Peter, H., Berner, R., Peters, A. M. J., Boehm, T. L. J., Plebani, A., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022020 · Cited by 678 · see citing works
Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses
Nishimura, H. (1998) · International Immunology · doi:10.1093/intimm/10.10.1563 · Cited by 500 · see citing works
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.
Strome, S. E., Dong, H., Tamura, H., Voss, S. G., Flies, D. B., Tamada, K., Salomão, D. R., Cheville, J. C., Hirano, F., Lin, W. Y., et al. (2003) · PubMed · Cited by 489 · see citing works
Peripheral development of B cells in mouse and man
Carsetti, R., Rosado, M. M., & Wardmann, H. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.0109.x · Cited by 479 · see citing works
PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model
Zhang, L., Gajewski, T. F., & Kline, J. P. (2009) · Blood · doi:10.1182/blood-2009-03-206672 · Cited by 409 · see citing works
CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans
Weller, S., Faili, A., Cordier, C., Braun, M. C., Deist, F. L., Basile, G. D. S., Hermine, O., Fischer, A., Reynaud, C., & Weill, J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.3.1166 · Cited by 398 · see citing works
Programmed Death-1 (PD-1) is a Marker of Germinal Center-associated T Cells and Angioimmunoblastic T-Cell Lymphoma
Dorfman, D. M., Brown, J. A., Shahsafaei, A., & Freeman, G. J. (2006) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000209855.28282.ce · Cited by 359 · see citing works
Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production.
Freeman, G. J., Borriello, F., Hodes, R. J., Reiser, H., Gribben, J. G., Ng, J. W., Kim, J., Goldberg, J. M., Hathcock, K. S., & László, G. (1993) · The Journal of Experimental Medicine · doi:10.1084/jem.178.6.2185 · Cited by 351 · see citing works
PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors
Zhang, J., Zhang, Z., Wang, X., Fu, J., Yao, J., Jiao, Y., Chen, L., Zhang, H., Wei, J., Jin, L., et al. (2007) · Blood · doi:10.1182/blood-2006-09-044826 · Cited by 298 · see citing works
A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator
Gonzalez, L. C., Loyet, K. M., Calemine-Fenaux, J., Chauhan, V., Wranik, B. J., Ouyang, W., & Eaton, D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409071102 · Cited by 252 · see citing works
PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1
Ghiotto, M., Gauthier, L., Serriari, N., Pastor, S., Truneh, A., Nunès, J. A., & Olive, D. (2010) · International Immunology · doi:10.1093/intimm/dxq049 · Cited by 230 · see citing works
Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2
Gavrieli, M., Watanabe, N., Loftin, S. K., Murphy, T. L., & MURPHY, K. M. M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.11.070 · Cited by 190 · see citing works
B and T Lymphocyte Attenuator Regulates B Cell Receptor Signaling by Targeting Syk and BLNK
Vendel, A. C., Calemine-Fenaux, J., Izrael-Tomasevic, A., Chauhan, V., Arnott, D. P., & Eaton, D. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.3.1509 · Cited by 118 · see citing works
PD-L2 is expressed on activated human T cells and regulates their function
Messal, N., Serriari, N., Pastor, S., Nunès, J. A., & Olive, D. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2011.06.436 · Cited by 116 · see citing works
Absence of Programmed Death Receptor 1 Alters Thymic Development and Enhances Generation of CD4/CD8 Double-Negative TCR-Transgenic T Cells
Blank, C. U., Brown, I., Marks, R., Nishimura, H., Honjo, T., & Gajewski, T. F. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.9.4574 · Cited by 111 · see citing works
High Expression of the Inhibitory Receptor BTLA in T-Follicular Helper Cells and in B-Cell Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia
M’Hidi, H., Thibult, M., Chetaille, B., Gondois‐Rey, F., Bouadallah, R., Nicollas, R., Olive, D., & Xerri, L. (2009) · American Journal of Clinical Pathology · doi:10.1309/ajcpphkgyyggl39c · Cited by 90 · see citing works
The Cytoskeleton Coordinates the Early Events of B-cell ActivationPreprint
Harwood, N. E., & Batista, F. D. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a002360 · Cited by 86 · see citing works
B and T Lymphocyte Attenuator Is Highly Expressed on CMV-Specific T Cells during Infection and Regulates Their Function
Serriari, N., Gondois‐Rey, F., Guillaume, Y., Remmerswaal, E. B. M., Pastor, S., Messal, N., Truneh, A., Hirsch, I., van Lier, R. A. W., & Olive, D. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902487 · Cited by 68 · see citing works
Blocking PD-1 in cancer immunotherapy
Dotti, G. (2009) · Blood · doi:10.1182/blood-2009-05-223412 · Cited by 33 · see citing works
Octamer binding protein 2 (Oct2) regulates PD-L2 gene expression in B-1 cells through lineage-specific activity of a unique, intronic promoter
Kaku, H., & Rothstein, T. L. (2009) · Genes and Immunity · doi:10.1038/gene.2009.68 · Cited by 20 · see citing works
Monoclonal antibodies to B and T lymphocyte attenuator (BTLA) have no effect on in vitro B cell proliferation and act to inhibit in vitro T cell proliferation when presented in a cis, but not trans, format relative to the activating stimulus
Zhang, M., Howard, K., Winters, A. G., Steavenson, S., Anderson, S. L., Smelt, S. C., Doellgast, G. J., Sheelo, C., Stevens, J., Kim, H., et al. (2010) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2010.04259.x · Cited by 8 · see citing works

Flagged first, then by citations

1 of the 45 references couldn’t be matched to a known paper.

Sorted by citations

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Martins, F., Sofiya, L., Sykiotis, G. P., Lamine, F., Maillard, M., Fraga, M., Shabafrouz, K., Ribi, C., Cairoli, A., Guex-Crosier, Y., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0218-0 · Cited by 2,314 · see citing works
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Alsaab, H. O., Sau, S., Alzhrani, R. M., Tatiparti, K., Bhise, K., Kashaw, S. K., & Iyer, A. K. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00561 · Cited by 1,715 · see citing works
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360 · see citing works
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
Ohaegbulam, K. C., Assal, A., Lázár‐Molnár, E., Yao, Y., & Zang, X. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.10.009 · Cited by 846 · see citing works
The role of HIF in immunity and inflammation
McGettrick, A. F., & O’Neill, L. A. J. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.08.002 · Cited by 768 · see citing works
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
Osorio, J. C., Ni, A., Chaft, J. E., Pollina, R., Kasler, M. K., Stephens, D., Rodriguez, C., Cambridge, L., Rizvi, H., Wolchok, J. D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw640 · Cited by 659 · see citing works
Clinical blockade of PD1 and LAG3 — potential mechanisms of action
Nguyen, L. T., & Ohashi, P. S. (2014) · Nature reviews. Immunology · doi:10.1038/nri3790 · Cited by 621 · see citing works
B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer
Hollern, D. P., Xu, N., Thennavan, A., Glodowski, C. R., García‐Recio, S., Mott, K. R., He, X., Garay, J. P., Carey-Ewend, K., Marron, D. L., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.028 · Cited by 470 · see citing works
Immune Checkpoint Inhibitors: Basics and Challenges
Li, B., Chan, H. L., & Chen, P. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170804143706 · Cited by 473 · see citing works
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas
Xu-Monette, Z. Y., Zhou, J., & Young, K. H. (2017) · Blood · doi:10.1182/blood-2017-07-740993 · Cited by 430 · see citing works
B lymphocytes and cancer: a love-hate relationship
Yuen, G. J., Demissie, E., & Pillai, S. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.10.010 · Cited by 433 · see citing works
PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
Liu, J., Chen, Z., Li, Y., Zhao, W., Wu, J., & Zhang, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.731798 · Cited by 421 · see citing works
Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis
Zhou, X., Yao, Z., Yang, H., Liang, N., Zhang, X., & Zhang, F. (2020) · BMC Medicine · doi:10.1186/s12916-020-01549-2 · Cited by 357 · see citing works
PD-1hi identifies a novel regulatory b-cell population in human hepatoma that promotes disease progression
Xiao, X., Lao, X.-M., Chen, M.-M., Liu, R.-X., Wei, Y., Ouyang, F.-Z., Chen, D.-P., Zhao, X.-Y., Zhao, Q., Li, X.-F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1408 · Cited by 352 · see citing works
Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer
Toi, Y., Sugawara, S., Sugisaka, J., Ono, H., Kawashima, Y., Aiba, T., Kawana, S., Saito, R., Aso, M., Tsurumi, K., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5860 · Cited by 352 · see citing works
Moving towards personalized treatments of immune-related adverse events
Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0352-8 · Cited by 351 · see citing works
Circulating and intrahepatic antiviral B cells are defective in hepatitis B
Burton, A. R., Pallett, L. J., McCoy, L. E., Suveizdytė, K., Amin, O. E., Swadling, L., Alberts, E., Davidson, B. R., Kennedy, P. T. F., Gill, U. S., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121960 · Cited by 327 · see citing works
PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma
Beldi‐Ferchiou, A., Lambert, M., Dogniaux, S., Vely, F., Vivier, É., Olive, D., Dupuy, S., Levasseur, F., Zucman, D., Lebbé, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12150 · Cited by 312 · see citing works
Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab
Toi, Y., Sugawara, S., Kawashima, Y., Aiba, T., Kawana, S., Saito, R., Tsurumi, K., Suzuki, K., Shimizu, H., Sugisaka, J., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0384 · Cited by 294 · see citing works
PD-1 blockade partially recovers dysfunctional virus–specific B cells in chronic hepatitis B infection
Salimzadeh, L., Bert, N. L., Dutertre, C., Gill, U. S., Newell, E. W., Frey, C., Hung, M., Novikov, N. Y., Fletcher, S. P., Kennedy, P. T. F., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121957 · Cited by 290 · see citing works
Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer
Iglesia, M. D., Vincent, B. G., Parker, J. S., Hoadley, K. A., Carey, L., Perou, C. M., & Serody, J. S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3368 · Cited by 276 · see citing works
Programmed death-1 pathway in cancer and autoimmunity
Pedoeem, A., Azoulay‐Alfaguter, I., Strazza, M., Silverman, G. J., & Mor, A. (2014) · Clinical Immunology · doi:10.1016/j.clim.2014.04.010 · Cited by 269 · see citing works
Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature
Spain, L. A., Walls, G., Julve, M., O’Meara, K., Schmid, T., Kalaitzaki, E., Turajlic, S., Gore, M. E., Rees, J. H., & Larkin, J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw558 · Cited by 263 · see citing works
Treg-mediated acquired resistance to immune checkpoint inhibitors
Saleh, R., & Elkord, E. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.003 · Cited by 238 · see citing works
Immune checkpoint inhibitor‐related hypophysitis and endocrine dysfunction: clinical review
Joshi, M., Whitelaw, B., Palomar, M. T. P., Wu, Y., & Carroll, P. (2016) · Clinical Endocrinology · doi:10.1111/cen.13063 · Cited by 224 · see citing works
HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function
Zhao, R., Chinai, J. M., Buhl, S., Scandiuzzi, L., Ray, A., Jeon, H., Ohaegbulam, K. C., Ghosh, K., Zhao, A., Scharff, M. D., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303524110 · Cited by 204 · see citing works
B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade
Kim, S. S., Shen, S. A., Miyauchi, S., Sanders, P. D., Pietryga, I. F., Mell, L. K., Gutkind, J. S., Cohen, E. E. W., Califano, J. A., & Sharabi, A. B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3211 · Cited by 200 · see citing works
The B-Side of Cancer Immunity: The Underrated Tune
Largeot, A., Pagano, G., Gonder, S., Moussay, E., & Paggetti, J. (2019) · Cells · doi:10.3390/cells8050449 · Cited by 180 · see citing works
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients
Cortellini, A., Chiari, R., Ricciuti, B., Metro, G., Perrone, F., Tiseo, M., Bersanelli, M., Bordi, P., Santini, D., Giusti, R., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.02.006 · Cited by 178 · see citing works
Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
Shergold, A. L., Millar, R., & Nibbs, R. J. B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104258 · Cited by 173 · see citing works
Bullous Pemphigoid: Trigger and Predisposing Factors
Moro, F., Fania, L., Sinagra, J. L., Salemme, A., & Zenzo, G. D. (2020) · Biomolecules · doi:10.3390/biom10101432 · Cited by 179 · see citing works
Multiplex Staining by Sequential Immunostaining and Antibody Removal on Routine Tissue Sections
Bolognesi, M. M., Manzoni, M., Scalia, C. R., Zannella, S., Bosisio, F. M., Faretta, M., & Cattoretti, G. (2017) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155417719419 · Cited by 170 · see citing works
T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells
Azzaoui, I., Uhel, F., Rossille, D., Pangault, C., Dulong, J., Le Priol, J., Lamy, T., Houot, R., Le Gouill, S., Cartron, G., et al. (2016) · Blood · doi:10.1182/blood-2015-08-662783 · Cited by 168 · see citing works
Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
Conway, J. R., Kofman, E., Mo, S. S., Elmarakeby, H., & Van Allen, E. (2018) · Genome Medicine · doi:10.1186/s13073-018-0605-7 · Cited by 165 · see citing works
Autoantibodies: Opportunities for Early Cancer Detection
Macdonald, I. K., Parsy-Kowalska, C. B., & Chapman, C. J. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.02.003 · Cited by 161 · see citing works
Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options
Velu, V., Shetty, R. D., Larsson, M., & Shankar, E. M. (2015) · Retrovirology · doi:10.1186/s12977-015-0144-x · Cited by 153 · see citing works
Cutaneous adverse events caused by immune checkpoint inhibitors
Quach, H. T., Johnson, D. B., LeBoeuf, N. R., Zwerner, J. P., & Dewan, A. K. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.09.054 · Cited by 149 · see citing works
Minimal PD-1 expression in mouse and human NK cells under diverse conditions
Judge, S. J., Dunai, C., Aguilar, E. G., Vick, S. C., Sturgill, I. R., Khuat, L. T., Stoffel, K. M., Dyke, J. V., Longo, D. L., Darrow, M. A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133353 · Cited by 142 · see citing works
B Cells and Tertiary Lymphoid Structures: Friends or Foes in Cancer Immunotherapy?
Lauss, M., Donia, M., Svane, I. M., & Jönsson, G. B. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1130 · Cited by 143 · see citing works
Landscape of infiltrating B cells and their clinical significance in human hepatocellular carcinoma
Zhang, Z., Ma, L., Goswami, S., Ma, J., Zheng, B., Duan, M., Liu, L., Zhang, L., Shi, J.-Y., Dong, L., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1571388 · Cited by 140 · see citing works
Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors
Kao, J. C., Brickshawana, A., & Liewluck, T. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0878-7 · Cited by 126 · see citing works
Cutaneous manifestations associated with immune checkpoint inhibitors
Watanabe, T., & Yamaguchi, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1071983 · Cited by 117 · see citing works
PD-1 immunobiology in systemic lupus erythematosus
Curran, C. S., Gupta, S., Sanz, I., & Sharon, E. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.10.025 · Cited by 111 · see citing works
Regulation of sister chromatid cohesion by nuclear PD-L1
Yu, J., Qin, B., Moyer, A. M., Nowsheen, S., Tu, X., Dong, H., Boughey, J. C., Goetz, M. P., Weinshilboum, R. M., Lou, Z., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0315-8 · Cited by 108 · see citing works
B cell checkpoints in autoimmune rheumatic diseases
Rubin, S. J. S., Bloom, M. S., & Robinson, W. H. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0211-0 · Cited by 107 · see citing works
Prognostic value of B cells in cutaneous melanoma
Selitsky, S. R., Mose, L. E., Smith, C. C., Chai, S., Hoadley, K. A., Dittmer, D. P., Moschos, S. J., Parker, J. S., & Vincent, B. G. (2019) · Genome Medicine · doi:10.1186/s13073-019-0647-5 · Cited by 106 · see citing works
Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer
Okoye, I., Houghton, M., Tyrrell, D. L., Barakat, K., & Elahi, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01215 · Cited by 104 · see citing works
Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid
Sowerby, L. M., Dewan, A. K., Granter, S. R., Gandhi, L., & LeBoeuf, N. R. (2017) · JAMA Dermatology · doi:10.1001/jamadermatol.2017.0091 · Cited by 101 · see citing works
Periodontal Ligament Stem Cells Regulate B Lymphocyte Function via Programmed Cell Death Protein 1
Liu, O., Xu, J., Ding, G., Liu, D., Fan, Z., Zhang, C., Chen, W., Ding, Y., Tang, Z., & Wang, S. (2013) · Stem Cells · doi:10.1002/stem.1387 · Cited by 100 · see citing works
Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis
Cautela, J., Zeriouh, S., Gaubert, M., Bonello, L., Laine, M., Peyrol, M., Paganelli, F. F., Lalevée, N., Barlési, F., & Thuny, F. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001887 · Cited by 96 · see citing works
IL-10-independent regulatory B-cell subsets and mechanisms of action
Ray, A., Wang, L., & Dittel, B. N. (2015) · International Immunology · doi:10.1093/intimm/dxv033 · Cited by 95 · see citing works
Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism
Yin, J., Wu, Y., Yang, X., Gan, L., & Xue, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.830631 · Cited by 95 · see citing works
Emerging Role of PD-1 in the Central Nervous System and Brain Diseases
Zhao, J., Roberts, A., Wang, Z., Savage, J. T., & Ji, R. (2021) · Neuroscience Bulletin · doi:10.1007/s12264-021-00683-y · Cited by 93 · see citing works
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart
Munir, A. Z., Gutierrez, A., Qin, J., Lichtman, A. H., & Moslehi, J. J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00715-5 · Cited by 94 · see citing works
Immune-Related Adverse Events Due to Cancer Immunotherapy: Immune Mechanisms and Clinical Manifestations
Casagrande, S., Sopetto, G. B., Bertalot, G., Bortolotti, R., Racanelli, V., Caffo, O., Giometto, B., Berti, A., & Veccia, A. (2024) · Cancers · doi:10.3390/cancers16071440 · Cited by 92 · see citing works
Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma
Kong, B. Y., Micklethwaite, K. P., Swaminathan, S., Kefford, R. F., & Carlino, M. S. (2016) · Melanoma Research · doi:10.1097/cmr.0000000000000232 · Cited by 86 · see citing works
The Immunomodulatory Effects of Mesenchymal Stem Cells on Regulatory B Cells
Liu, J., Liu, Q., & Chen, X. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01843 · Cited by 86 · see citing works
PD-1 as an Immune Modulatory Receptor
Yao, S., & Chen, L. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000060 · Cited by 83 · see citing works
Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies
Hwang, S. J. E., Carlos, G., Chou, S., Wakade, D., Carlino, M. S., & Fernández‐Peñas, P. (2016) · Melanoma Research · doi:10.1097/cmr.0000000000000260 · Cited by 82 · see citing works
Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition
Siefker-Radtke, A. O., & Curti, B. D. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.190 · Cited by 82 · see citing works
IRF4 Activity Is Required in Established Plasma Cells to Regulate Gene Transcription and Mitochondrial Homeostasis
Low, M. S. Y., Brodie, E. J., Fedele, P. L., Liao, Y., Grigoriadis, G., Strasser, A., Kallies, A., Willis, S. N., Tellier, J., Shi, W., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.097 · Cited by 81 · see citing works
Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota
Fidelle, M., Yonekura, S., Picard, M., Cogdill, A. P., Hollebecque, A., Roberti, M. P., & Zitvogel, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.600886 · Cited by 82 · see citing works
Control of NK Cell Activation by Immune Checkpoint Molecules
Beldi‐Ferchiou, A., & Caillat‐Zucman, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102129 · Cited by 77 · see citing works
Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation
Yang, H., Yao, Z., Zhou, X., Zhang, W., Zhang, X., & Zhang, F. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108377 · Cited by 74 · see citing works
Pathogenic, glycolytic PD-1+ B cells accumulate in the hypoxic RA joint
Floudas, A., Neto, N. G. B., Marzaioli, V., Murray, K., Moran, B., Monaghan, M. G., Low, C., Mullan, R. H., Rao, N. L., Krishna, V., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.139032 · Cited by 73 · see citing works
Risk factors for immune-related adverse events: what have we learned and what lies ahead?
Liu, X., Shi, Y., Zhang, D., Zhou, Q., Liu, J., Chen, M., Xu, Y., Zhao, J., Zhong, W., & Wang, M. (2021) · Biomarker Research · doi:10.1186/s40364-021-00314-8 · Cited by 73 · see citing works
The role of B lymphocytes in the immuno-biology of non-small-cell lung cancer
Patel, A. J., Richter, A. G., Drayson, M. T., & Middleton, G. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02461-2 · Cited by 71 · see citing works
Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment
Wang, M., Liu, Y., Cheng, Y., Wei, Y., & Wei, X. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.12.002 · Cited by 66 · see citing works
Autoantibodies in Patients With Immune-Related Adverse Events From Checkpoint Inhibitors
Ghosh, N., Chan, K. K., Jivanelli, B., & Bass, A. R. (2021) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000001777 · Cited by 65 · see citing works
Activation of B cells in Tertiary Lymphoid Structures in cancer: Anti-tumor or anti-self?
Fridman, W. H., Sibéril, S., Pupier, G., Soussan, S., & Sautès‐Fridman, C. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101703 · Cited by 64 · see citing works
The role of the immunosuppressive PD-1/PD-L1 checkpoint pathway in the aging process and age-related diseases
Salminen, A. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02444-6 · Cited by 61 · see citing works
Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know
Camelliti, S., Noci, V. L., Bianchi, F., Moscheni, C., Arnaboldi, F., Gagliano, N., Balsari, A., Garassino, M. C., Tagliabue, E., Sfondrini, L., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01721-9 · Cited by 61 · see citing works
IDH2 and TET2 mutations synergize to modulate T Follicular Helper cell functional interaction with the AITL microenvironment
Leca, J., Lemonnier, F., Meydan, C., Foox, J., Ghamrasni, S. E., Mboumba, D.-L., Duncan, G. S., Fortin, J., Sakamoto, T., Tobin, C., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.01.003 · Cited by 60 · see citing works
Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature
Zumelzu, C., Alexandre, M., Roux‐Villet, C. L., Weber, P. A., Guyot, A., Levy, A., Aucouturier, F., Grootenboer‐Mignot, S., Caux, F. A., Maubec, E., et al. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00268 · Cited by 60 · see citing works
PD-1/PD-L1 axis: implications in immune regulation, cancer progression, and translational applications
Ortega, M. A., Boaru, D. L., León-Oliva, D. D., Fraile‐Μartinez, O., Montero, C. G., Rios, L., Garrido-Gil, M. J., Barrena-Blázquez, S., Minaya‐Bravo, A., Rios‐Parra, A., et al. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02463-3 · Cited by 62 · see citing works
Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer
Aso, M., Toi, Y., Sugisaka, J., Aiba, T., Kawana, S., Saito, R., Ogasawara, T., Tsurumi, K., Ono, K., Shimizu, H., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0550 · Cited by 58 · see citing works
Single-cell spatial architectures associated with clinical outcome in head and neck squamous cell carcinoma
Blise, K. E., Sivagnanam, S., Banik, G. L., Coussens, L. M., & Goecks, J. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00253-z · Cited by 58 · see citing works
Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types
Lepone, L. M., Donahue, R. N., Grenga, I., Metenou, S., Richards, J., Heery, C. R., Madan, R. A., Gulley, J. L., & Schlom, J. (2016) · Journal of Circulating Biomarkers · doi:10.5772/62322 · Cited by 57 · see citing works
The Terrible Triad of Checkpoint Inhibition: A Case Report of Myasthenia Gravis, Myocarditis, and Myositis Induced by Cemiplimab in a Patient with Metastatic Cutaneous Squamous Cell Carcinoma
Jeyakumar, N., Etchegaray, M., Henry, J. T., Lelenwa, L. C., Zhao, B., Segura, A., & Buja, L. M. (2020) · Case Reports in Immunology · doi:10.1155/2020/5126717 · Cited by 57 · see citing works
Phenotypic and Functional Characterization of Double Negative B Cells in the Blood of Individuals With Obesity
Frasca, D., Diaz, A., Romero, M., & Blomberg, B. B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.616650 · Cited by 56 · see citing works
Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors
Reul, J., Frisch, J., Engeland, C. E., Thalheimer, F. B., Hartmann, J., Ungerechts, G., & Buchholz, C. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00052 · Cited by 56 · see citing works
Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment
Zhao, Z., Xiao, X., Saw, P. E., Wu, W., Huang, H., Chen, J., & Nie, Y. (2019) · Science China Life Sciences · doi:10.1007/s11427-019-9665-8 · Cited by 56 · see citing works
PD-L1 promotes myofibroblastic activation of hepatic stellate cells by distinct mechanisms selective for TGF-β receptor I versus II
Sun, L., Wang, Y., Wang, X., Navarro‐Corcuera, A., Ilyas, S. I., Jalan‐Sakrikar, N., Gan, C., Tu, X., Shi, Y. H., Tu, K., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110349 · Cited by 55 · see citing works
Paradoxical aging in HIV: immune senescence of B Cells is most prominent in young age
Rinaldi, S., Pallikkuth, S., George, V. K., de Armas, L. R., Pahwa, R., Sanchez, C. M., Pallin, M., Pan, L., Cotugno, N., Dickinson, G. M., et al. (2017) · Aging · doi:10.18632/aging.101229 · Cited by 55 · see citing works
Immune Checkpoints in Viral Infections
Cai, H., Liu, G., Zhong, J., Zheng, K., Xiao, H., Li, C., Song, X., Li, Y., Xu, C., Wu, H., et al. (2020) · Viruses · doi:10.3390/v12091051 · Cited by 54 · see citing works
Pigs expressing the human inhibitory ligand PD ‐L1 ( CD 274) provide a new source of xenogeneic cells and tissues with low immunogenic properties
Buermann, A., Petkov, S., Petersen, B., Hein, R., Lucas‐Hahn, A., Baars, W., Brinkmann, A., Niemann, H., & Schwinzer, R. (2018) · Xenotransplantation · doi:10.1111/xen.12387 · Cited by 54 · see citing works
Neoantigen cancer vaccine augments anti-CTLA-4 efficacy
Salvatori, E., Lione, L., Compagnone, M., Pinto, E., Conforti, A., Ciliberto, G., Aurisicchio, L., & Palombo, F. (2022) · npj Vaccines · doi:10.1038/s41541-022-00433-9 · Cited by 52 · see citing works
Immune Checkpoints in Cancers: From Signaling to the Clinic
Pisibon, C., Ouertani, A., Bertolotto, C., Ballotti, R., & Chéli, Y. (2021) · Cancers · doi:10.3390/cancers13184573 · Cited by 49 · see citing works
MPLA shows attenuated pro‐inflammatory properties and diminished capacity to activate mast cells in comparison with LPS
Schülke, S., Flaczyk, A., Vogel, L., Gaudenzio, N., Angers, I., Löschner, B., Wolfheimer, S., Spreitzer, I., Qureshi, S. T., Tsai, M. M., et al. (2015) · Allergy · doi:10.1111/all.12675 · Cited by 49 · see citing works
Plasmablast‐like Phenotype Among Antigen‐Experienced CXCR5 – CD19 low B Cells in Systemic Lupus Erythematosus
Szelinski, F., Stefanski, A., Schrezenmeier, E. V., Rincón-Arévalo, H., Wiedemann, A., Reiter, K., Ritter, J., Lettau, M., Dang, V. D., Fuchs, S. P., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42157 · Cited by 53 · see citing works
PD-1/PD-L1 inhibitors for advanced or metastatic cervical cancer: From bench to bed
Huang, W., Liu, J., Xu, K. L., Chen, H., & Bian, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.849352 · Cited by 47 · see citing works
Checkpoint inhibitor immune-related adverse events: A focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities
Taylor, J., Gandhi, A., Gray, E. S., & Zaenker, P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991433 · Cited by 47 · see citing works
Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: Diagnosis, mechanism, and treatment strategies
Guo, X., Chen, S., Wang, X., & Liu, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1138483 · Cited by 46 · see citing works
Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients
Tan, Q., Wang, D., Yang, J., Xing, P., Yang, S., Li, Y., Qin, Y., He, X., Liu, Y., Zhou, S., et al. (2020) · Theranostics · doi:10.7150/thno.45816 · Cited by 44 · see citing works
Noninvasive Imaging of Cancer Immunotherapy
Abousaway, O., Rakhshandehroo, T., den Abbeele, A. D. V., Kircher, M. F., & Rashidian, M. (2020) · Nanotheranostics · doi:10.7150/ntno.50860 · Cited by 43 · see citing works
Immune checkpoint inhibitors in cervical cancer: Current status and research progress
Xie, Y., Kong, W., Zhao, X., Zhang, H., Luo, D., & Chen, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.984896 · Cited by 43 · see citing works
Germinal center-dependent and -independent immune responses of tumor-infiltrating B cells in human cancers
Playoust, E., Remark, R., Vivier, É., & Milpied, P. J. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01060-7 · Cited by 42 · see citing works
Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy
Miller, N. J., Church, C. D., Fling, S. P., Kulikauskas, R. M., Ramchurren, N., Shinohara, M. M., Kluger, H. M., Bhatia, S., Lundgren, L. M., Cheever, M. A., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0450-7 · Cited by 42 · see citing works
Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1
Havunen, R., Kalliokoski, R., Siurala, M., Sorsa, S., Santos, J. M., Cervera-Carrascón, V., Anttila, M. O., & Hemminki, A. (2021) · Cells · doi:10.3390/cells10020246 · Cited by 43 · see citing works
Activated B cells suppress T-cell function through metabolic competition
Imahashi, N., Başar, R., Huang, Y., Wang, F., Baran, N., Banerjee, P. P., Lu, J., Cortes, A. K. N., Uprety, N., Ensley, E. L., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005644 · Cited by 42 · see citing works

PD-1 is a novel regulator of human B-cells activation
Thibult, M., Mamessier, É., Gertner-Dardenne, J., Pastor, S., Just‐Landi, S., Xerri, L., Chetaille, B., & Olive, D. (2012)
For permissions, please
Thibult, M., Mamessier, É., Gertner-Dardenne, J., Pastor, S., Just‐Landi, S., Xerri, L., Chetaille, B., & Olive, D. (2012)
B cell activation and induced antibody responses to porcine antigen can be diminished by PD‐L1‐mediated triggering of PD‐1
Buermann, A., Borns, K., Römermann, D., Plege, A., & Schwinzer, R. (2014) · Xenotransplantation · doi:10.1111/xen.12083_18 · Cited by 1 · see citing works
No evidence for dualism in function and receptors: PD‐L2/B7‐DC is an inhibitory regulator of human T cell activation
Grabmeier‐Pfistershammer, K., Klauser, C., Pickl, W. F., Stöckl, J., Leitner, J. M., Zlabinger, G. J., Majdic, O., & Steinberger, P. (2006) · European Journal of Immunology · doi:10.1002/eji.200535344 · Cited by 50 · see citing works
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · see citing works

Authors: Thibult, M.-L., Mamessier, E., Gertner-Dardenne, J., Pastor, S., Just-Landi, S., Xerri, L., Chetaille, B., & Olive, D.
Affiliations: Inserm (FR)
Centre de Recherche en Cancérologie de Marseille (FR)
ORCID: Pastor, Sonia
Xerri, Luc
Olive, Daniel
Venue: International Immunology
Publisher: Oxford University Press (OUP)
Published: 2012-10-18
Volume: 25
Issue: 2
Pages: 129-137
ISSN: 0953-8178 (ISSN-L)
1460-2377
DOI: 10.1093/intimm/dxs098
OpenAlex: W2131640081
Cited by: 365
References: 45
Citations by year: 2026: 16 · 2025: 28 · 2024: 38 · 2023: 25 · 2022: 44 · 2021: 43 · 2020: 47 · 2019: 38 · 2018: 27 · 2017: 20 · 2016: 19 · 2015: 8 · 2014: 8 · 2013: 4
FWCI: 2.79
Type: journal article
Language: en
Open access: closed
Locations: International Immunology (publishedVersion)
PubMed (publishedVersion)
HAL (submittedVersion)
Topics: Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
Keywords: PD-1, PD-L1, PD-L2, B cell activation, B cell receptor signaling, TLR9, naive B cells, memory B cells, germinal center B cells, B cell proliferation, inflammatory cytokines
MeSH terms: B-Lymphocytes, Humans, Lymphocyte Activation, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

PD-1 is a novel regulator of human B-cell activation

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks